Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
China Medical Univ. XO compound S40: sourced facts only. name: "Among the synthesized derivatives, S40 exhibited potent XO inhibitory activity comparable to TS10 and showed stable interactions within the XO active site as demonstrated by molecular modeling." [PMID:42594682]; target: "Among the synthesized derivatives, S40 exhibited potent XO inhibitory activity comparable to TS10 and showed stable interactions within the XO active site as demonstrated by molecular modeling." [PMID:42594682]; developer: "School of Pharmacy, Key Laboratory of Research and Development of Small Molecule Targeted Antitumor Drugs, China Medical University, 77 Puhe Road, North New Area, Shenyang, 110122, China." [PMID:42594682]; stage: "In hyperuricemic rat models, S40 dose-dependently reduced serum uric acid levels and ameliorated renal and hepatic histopathological damage." [PMID:42594682]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on China Medical Univ. XO compound S40.